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Abstract
Myelodysplastic syndromes are heterogeneous group of clonal hematologic malig-
nancies characterized by peripheral blood cytopenias secondary to the ineffective
hematopoiesis. ADs are frequently reported in MDS, the incidence ranging from 10 to
30%, and particularly ADs are more frequently seen at CMML. ADsmay prone patient
to MDS, especially when immune suppressors such as azathioprine are used for the
underlying AD. Both innate and adaptive immune systems, and different cytokines
including interleukins, TNF-α, and C-X-C motif chemokine 10 (CXCL10) contribute
in immune dysregulation of MDS. Vasculitis, seronegative rheumatoid arthritis, SLE,
Behçet’s disease, RP, and AIHA are just some of the ADs occurring concomitantly with
MDS. Although hematopoietic growth factors are recommended by the American
Society of Clinical Oncology (ASCO), it has been recognized from several case reports
that treatment of the underlying MDSmay resolve the associated autoimmune disor-
ders. The heterogeneity and complexity of pathology, clinical manifestations, response
to therapy, and prognosis of MDS and its immune dysregulationmake the prognosis of
MDS with autoimmune diseases a matter of debate. Better understanding of the
immune dysregulation of MDS in the molecular level may help to design prospective,
double blind clinical trials to find the best treatment options for autoimmune disorders
associated with MDS.
Keywords: autoimmune disorders (ADs), myelodysplastic syndrome (MDS),
chronic myelomonocytic leukemia (CMML), Behçet’s disease, systemic lupus
erythematosus (SLE), azathioprine, azacitidine, tumor necrosis factor alpha
(TNF-α), regulatory T-cells (Treg), autoimmune hemolytic anemia (AIHA),
vasculitis, chronic inflammatory demyelinating polyneuropathy (CIDP),
neutrophilic dermatosis, Henoch-Schonlein purpura, relapsing polychondritis (RP),
granulomatosis with polyangiitis (GPA), giant cell arteritis (GCA), polyarteritis
nodosa (PAN)
1. Introduction
Myelodysplastic syndromes (MDS) are characterized by peripheral blood
cytopenias secondary to the ineffective hematopoiesis, and represent a heteroge-
neous group of clonal hematologic malignancies in which abnormal multipotent
progenitor cells are involved. As a result, there is an increased risk of bleeding
diathesis and anemia requiring frequent transfusions, infections, and progression to
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acute myeloid leukemia [1–4]. It is a very well-known fact that a large spectrum of
genetic mutations is involved in MDS pathogenesis that may affect clinical outcome
and response to the treatment. These genetic mutations may control cell cycle by
affecting key proteins of spliceosome, DNA repair, kinase signaling, tumor sup-
pressor genes, and transcription factors, changing bone marrow micro environ-
ment, resulting in hypercellular bone marrow with peripheral cytopenias through
enhanced programmed cell death (PCD) and bone marrow dysfunction [5, 6]. To
overcome programmed cell death, hematopoietic growth factors such as erythro-
poiesis stimulating agents (ESAs) and granulocyte colony stimulating factor (G-
CSF) are the 1st step in management of the low-grade MDS recommended by the
American Society of Clinical Oncology (ASCO) to reduce early apoptosis [1].
Thrombopoietic stimulating agents (TSAs), ESAs, G-CSF, antithymocyte glob-
ulin (ATG) [7], lenalidomide [8], and hypomethylating agents are some of the non-
transplantation options for management of the MDS patients suggesting that
immune dysregulation plays a pivotal role in MDS pathogenesis [1]. Although its
etiology is not clear, it has been shown that natural killer (NK) cell activity and its
response to chemokines is decreased in MDS, and natural killer cells will be pro-
gressively more dysfunctional with MDS progression [9]. It has been shown that
although dysfunctional regulatory T-cells (Treg), cells in charge of suppressing
T helper (Th) activity, contribute in early stages of MDS, Th expands in the later
stages of MDS, and there function is significantly reduced with treatment [10].
Tumor necrosis factor alpha (TNF-α) level is higher in bone marrow and
peripheral blood plasma of MDS patients, and may reflect an unfavorable outcome
[11, 12]. Study shows that plasma level of 19 cytokines are significantly altered
compared with normal individuals, among all of them, C-X-C motif chemokine
10 (CXCL10) and interleukin 6 were associated with shortened survival [13]. The
relationship between shorter survival and interleukin 6 levels is very well known,
and high producing genotypes of both TNF-α and interleukin 6 are highly associ-
ated with transfusion dependency for both anemia and thrombocytopenia, and
severity of the bicytopenias [14]. Interferon regulatory factor-1 (IRF-1), a tran-
scriptional activator of interferon system, has anti oncogenic properties, inhibits
tumor formation, and regulates innate immune response. It has been shown that
IRF-1 mRNA is 10 fold decreased in MDS patients, while it is increased in MDS
patients with autoimmune disorders, showing that IRF-1 may promote inflamma-
tion and autoimmunity and has a protective roll in MDS patient’s [15].
Although it has been reported that MDS is significantly associated with autoim-
mune disorders, it may occur secondary to the autoimmune disorders per se [16] or
exposure to the therapeutic agents used for treatment of autoimmune disorders.
A retrospective study in Sweden on 1662 MDS patients and 42,878 matched controls
revealed that underlying autoimmune disorder increased risk of MDS by 2.1 with
highest risks observed with prior autoimmune hemolytic anemia (AIHA),
polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA), giant cell
arteritis (GCA) and aplastic anemia. It was speculated that chronic stimulation of
the immune system may act as a trigger and prone the patient to MDS [17]. In a
retrospective study of 2471 patients, it was found that MDS occurred subsequent to
autoimmune disorders, most commonly rheumatoid arthritis, Sjogren’s syndrome,
systemic lupus erythematosus, polyarteritis nodosa, discoid lupus erythematosus,
and pernicious anemia were associated with MDS [18]. In a case control study of
80 for MDS patients, it was found that there is strong and statistically significant
evidence that MDS occurred after autoimmune disorders with Grave’s disease and
Hashimoto’s thyroiditis were among the most important disorders [19]. There is a
case report of limited granulomatosis with polyangiitis (GPA) treated with cortico-
steroids, who did develop myelodysplastic syndrome, papillary thyroid carcinoma,
and gastric adenocarcinoma [20].
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There are several reports regarding therapy related MDS in population with
autoimmune disorders who underwent disease modifying antirheumatic drugs
(DMARDs) therapy. In a retrospective case-control study of 40,011 patients with 27
kinds of autoimmune disorders, 311 patients met the inclusion criteria, 86 of them
had MDS, and found azathioprine exposure has increased 7 fold myeloid neoplasms
in a median of 8 years. In this study, methotrexate, and mycophenolate mofetil did
not elevate the risk of myeloid neoplasms [21]. However, there is a case report
regarding association of low-dose oral methotrexate therapy with MDS in a rheu-
matoid arthritis patient [22]. In another study, from 370 rheumatologic patients
who received azathioprine for at least 1 year, 59 patients underwent bone marrow
examination and 2 of them found to have MDS. This study revealed that risk of
secondary MDS is 100 fold higher in patients who received azathioprine for their
rheumatologic disorders. Chromosomal examination of the patients with MDS sec-
ondary to the azathioprine showed abnormalities of chromosome 7 in majority of
them (8 out of 10) [23]. There is also evidence that MDS patients who have
autoimmune disorders might respond to hypomethylating agents such as
azacitidine and decitabine [24].
2. Rheumatologic manifestations of MDS
It is a very well-known fact that about 10–30% of MDS patients may present
with a variety of autoimmune or laboratory manifestations or develop an autoim-
mune disorder. These manifestations are polymorphic and include leukocytoclastic
vasculitis, clubbing, peripheral neuropathy, autoimmune hemolytic anemia,
polyarthritis, myositis, acute or systemic vasculitis, Raynaud’s phenomenon,
polyarteritis nodosa, vitiligo, iritis, colonic ulcerations, pulmonary involvement,
and reported autoimmune disorders include rheumatoid arthritis, Sjogren’s disease,
giant cell arteritis, polymyalgia rheumatica, relapsing polychondritis, Behçet’s dis-
ease, and systemic lupus erythematosus. Although autoimmune manifestations are
mostly seen during the course of MDS, autoimmune disorders may occur before
MDS diagnosis. Laboratory manifestations of MDS include hypergammaglo-
bulinemia, hypogammaglobulinemia, monoclonal gammopathy, positive direct
antiglobulin test (DAT), positive ANA, rheumatoid factor, cryoglobulinemia, and
anti-double-stranded DNA.
3. Autoimmune disorders in myelodysplastic syndrome
Several studies support that autoimmune disorders may occur in the setting of
MDS, and treating MDS with immunosuppressors may improve the autoimmune
disorder. Although there were several case reports of MDS preceding autoimmune
disorders, the first comprehensive retrospective study in 1986 on 104 MDS patients
revealed two patients had pernicious anemia, two had hypothyroidism, and one had
both pernicious anemia and hypothyroidism [23]. Later, in a retrospective study in
1994, five patients with MDS reviewed and revealed polyarthritis with positive
rheumatoid factor (RF) and necrotizing vasculitis [25]. In another retrospective
study in 1995, 221 patients with MDS reviewed and found 30 patients with autoim-
mune disorders, and categorized patient to three categories of acute systemic vas-
culitis or autoimmune disorder, chronic or isolated autoimmune phenomena, and
classic connective tissue disorders. Skin vasculitis, arthritis, and fever were among
the most common autoimmune manifestations [26].
A case series in 2002 showed various autoimmune paraneoplastic disorders
including vasculitis, pyoderma gangrenosum, Coombs negative autoimmune
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hemolytic anemia, autoimmune thrombocytopenia, and chronic inflammatory
demyelinating polyneuropathy (CIDP) with good response to immunosuppressive
therapy [27]. In a retrospective review of 235 MDS patients autoimmune manifes-
tations such as skin vasculitis (24%), noninfectious fever (13%), arthralgia and
arthritis (13%), peripheral neuropathy (10%), and pulmonary infiltrates (8%) were
more common than systemic vasculitis [28]. In a cohort of 1408 patients with MDS,
391 (28%) had autoimmune disorders, with hypothyroidism (44%), as the most
prevalent, and idiopathic thrombocytopenic purpura (12%), rheumatoid arthritis
(10%), and psoriasis (7%) were among the common manifestations of autoimmune
diseases [29].
In a retrospective study of 67 MDS patients with autoimmune diseases, neutro-
philic dermatosis was the most common autoimmune disease (35.8%), followed by
Behçet’s disease (14.9%), and rheumatoid arthritis (13.4%) [30].
3.1 Vasculitis
The association between MDS and vasculitis is rare, but more common than
solid tumors, and has been described for decades. Cutaneous vasculitis presents
by palpable purpura mainly in lower extremities that involves small vessels and
is characterized by perivascular inflammation and vessel wall damage by
infiltrating neutrophils. Although both cutaneous and systemic vasculitis has been
reported in MDS patients, at times they can be seen together in MDS patients. For
instance, in a case series of 6 biopsy proven cutaneous vasculitis patients with MDS,
3 patients had evidence of systemic vasculitis [31]. In one case, MDS patient
with biopsy proven cutaneous vasculitis developed acute myeloid leukemia
within 4 months of vasculitis diagnosis [32]. Henoch-Schonlein purpura, a small
vessel vasculitis with IgA dominant immune deposits has been described in MDS
patients [33].
The association of MDS and polyarteritis nodosa (PAN) type medium-vessel
vasculitis has been reported [34]. In a retrospective study of 8 patients with chronic
myelomonocytic leukemia (CMML), with vasculitis involved the medium-vessel,
fulfilling the criteria for classic PAN, the presentation was non-specific, and
patients developed atypical manifestations [35]. There is a case report of 43-year-
old man who qualified for a diagnosis of PAN and developed systemic vasculitis at
the time of chronic myelomonocytic leukemia (CMML) diagnosis [36]. There is a
report of two cases with CMML who presented with PAN-like systemic vasculitis
with bilateral perirenal hemorrhage and negative antineutrophil cytoplasmic anti-
body with improvement of vasculitis with systemic steroids [37].
Although most MDS associated vasculitis described as leukocytoclastic vasculi-
tis, published case reports documented large vessel vasculitis as autoimmune com-
plication of MDS. Aortitis has been reported as an autoimmune manifestation of an
MDS patient at presentation [38]. There is a report of two MDS cases that presented
with acute large vessel vasculitis with rapid improvement with systemic steroids
[39]. In a retrospective analysis of 271 temporal arteritis patients, it was found that
20 patients had malignancy, of which 11 patients had MDS, favoring a relationship
between large vessel vasculitis and MDS [40]. There is a case report of Takayasu’s
arteritis diagnosed shortly after diagnosis of MDS, with progression to AML
regardless of improvement of vasculitis with immunosuppressive treatment [41].
There is a case report of a 71-year-old woman presenting with fever, neck
pain, anemia, and thrombocytopenia, with positive positron emission tomography
(PET)/CT scan of the aorta and carotid arteries with negative temporal artery
biopsy who received the diagnosis of MDS after a bone marrow aspiration
analysis [42, 43].
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3.2 Behçet’s disease
A multisystem, chronic inflammatory disease of unknown etiology, Behçet’s
disease (BD) is characterized by recurrent oral and genital ulcers, uveitis, arthritis,
and vascular involvement of several organs including pulmonary, central nervous
system and gastrointestinal tract. In a retrospective study of 805 BD patients,
16 patients had MDS, from which 43.8% had BD prior to MDS, 18.7% diagnosed
after MDS and 37.5% had concurrent BD and MDS. It has been shown that trisomy
8 has been accumulated in all of BD patients with MDS, and these patients more
likely to be female, older age, and have fever and ileocecal ulcerations [44]. In a
retrospective study of 46 MDS patients, 8 patients had trisomy 8, 5 of them had
multiple intestinal ulcers, a common feature of BD. Two of the MDS patients with
trisomy 8 and multiple intestinal ulcers were treated with granulocyte-colony stim-
ulating factor (G-CSF), aggravating their symptoms, suggesting G-CSF should be
used cautiously in this subgroup of MDS patients [45]. There is several case reports
of BD associated with MDS [46–49]. In a case report of two patients with BD and
MDS, it has been suggested that PET/CT may help diagnosis of both BD and MDS
with high uptake by bone marrow in MDS patients and genital and gastrointestinal
aphthous ulcers in BD patients [50]. It has been suggested that the frequency of
gastrointestinal involvement is more common in MDS-associated BD patients than
general BD population [51].
3.3 Inflammatory arthritis
There are several case reports and small series of inflammatory arthritis and
MDS co-occurrence. In a retrospective study of 28 MDS patients, 8 had acute
seronegative inflammatory arthritis with good response of arthritis to steroids [52].
In a French multicenter retrospective study of 22 patients with MDS, 77% of
patients had polyarthritis, and 68% had symmetric joint involvement. Radiologic
erosions are rare, and MDS associated arthritis is more frequent in refractory ane-
mia with excess blast (RAEB) [53].
3.4 Miscellaneous
There are several case reports of relapsing polychondritis (RP) presenting as a
paraneoplastic disorder in the setting of MDS [54, 55]. In a retrospective study of
hematological changes in 19 patients with relapsing polychondritis, MDS was found
in three RP patients [56]. Autoimmune hemolytic anemia has been reported in
association with MDS [57–59]. Association of systemic lupus erythematosus and
MDS has been reported [60–62].
3.5 Immunological abnormalities
It is a very well-known fact that a spectrum of immunological abnormalities
occur in MDS. In a retrospective study of 104 MDS patients, 12.5% had monoclonal
gammopathy, 19% had low immunoglobulin levels, 32% had polyclonal rise in
serum immunoglobulin level, and 8.1% had positive direct antiglobulin test (DAT)
[25]. In a case series of 142 patients with MDS and CMML, 23.2% had non-organ
specific autoantibody ANA as the most frequent serologic finding [25]. Thrombo-
cytopenia is a common finding in MDS, and can be seen in up to two third of the
patients. In a study of 54 MDS patients with no treatment of transfusions, direct
platelet immunofluorescence test for platelet associated IgG was positive in 28
patients. Patients with higher amount of platelet associated IgG, had significantly
higher mean platelet volume (MPV), thrombocytopenia and worse outcome [63].
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4. Prognosis
It has been suggested that appearance of skin vasculitis in MDS patients may
reflect acute myeloid leukemia transformation. In a prospective study of 157 MDS
patients for a median of 44 months, 15 patients (9.55%) experienced skin lesions,
and neutrophilic dermatosis (7, 4.46%), specific lesions (5, 3.18%), cutaneous vas-
culitis (2, 1.27%) and Behçet’s disease (1, 0.63%) were reported. This study revealed
that neutrophilic dermatosis was more prevalent in MDS patients, may confer the
higher risk of acute myeloid leukemia transformation [64]. In another study of 84
newly diagnosed MDS patients, correlation of cutaneous findings with immuno-
logic parameters and prognostic features of MDS examined, and revealed that 21
patients had skin lesions at presentation, and skin manifestations were a significant
predictor of the high-risk MDS subgroup [65].
In a retrospective study of 153 MDS patients, 12% had autoimmune diseases, and
63% has at least one immunological abnormality in test results. In this study, the
survival of patients without autoimmune diseases was better than patients with
autoimmune disease [66]. However, in a 4 year prospective study of 70 MDS
patients, 53 patients without and 13 patients with autoimmune disease, there was no
particular difference concerning prognosis between two groups. And patients with
autoimmune diseases were not statistically different in survival compared with
MDS patients without autoimmune disease [67].
5. Treatment
Autoimmune disorders associated with MDS may predate or occur after MDS
diagnosis, and their treatment many be associated with significant side effects in
MDS patients. It has been recognized from several case reports that treatment of the
underlying MDS may resolve the associated autoimmune disorders. In a transfusion
dependent MDS patient who was receiving G-CSF and erythropoietin, neutrophilic
dermatosis did not improve with G-CSF withholding. Two months after starting 5-
azacitidine, a hypomethylating agent, the skin rash completely resolved, and did
not recur after 2 years [68]. In another case series of 3 MDS patients with autoim-
mune disorders, 5-azacitidine improved both MDS and autoimmune disorders
although long term steroid could not be tapered [69].
In a retrospective study of 123 MDS patients with autoimmune disorders, 118
patients (96%) were treated with steroids, and 48% of patients were required a
second line treatment for refractory disease or relapse. Although autoimmune dis-
order treatment did not improve MDS, MDS treatment with 5-azacitidine improved
the autoimmune disorder in 9 out of 11 (80%) of patients [70]. In another retro-
spective study of 123 MDS/CMML patients with autoimmune disorders, 28 patients
received at least 5 cycles of azacitidine, 20 of them did not respond to steroids. In
86% of MDS/CMML patients, clinical autoimmune syndromes improved by
azacitidine, and prednisone dose tapered in 64% of patients [71].
The overall effect of biologic medications efficacy in MDS patients who
presented with autoimmune disorder is not clear. As of today, there is only one
retrospective study of MDS patients with autoimmune disorders and biologic med-
ications. In this study of at least one biologic medication, 29 patients followed for at
least 3 years. 89% of patients received a biologic after failure or intolerance of two
disease modifying anti rheumatic agents (DMARDs), however, 11% of patients
received biologics as a first line treatment. Except rituximab, a CD-20 blocker,
mainly for vasculitis (58% response), there was partial or insufficient response to
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TNF-α antagonists, and their efficacy is much less in autoimmune disorders associ-
ated with MDS than autoimmune disorders without MDS. Overall, response rate to
5-azacitidine in MDS-associated autoimmune disorders was 67% in favor of a cau-
sality relationship between MDS and autoimmune disorders [72].
6. Conclusion
Myelodysplastic syndromes are a heterogeneous group of progressive clonal
hematopoietic stem cell disorders characterized by a varying degree of peripheral
cytopenia, and increased probability of transformation to acute myeloid leukemia.
MDS and particularly CMML are frequently associated with a variety of autoimmune
disorders that can be diagnosed concomitantly with MDS or before or after MDS.
The heterogeneity and complexity of pathology, clinical manifestations, response to
therapy, and prognosis of MDS and its immune dysregulationmakes the prognosis of
MDS with autoimmune diseases a matter of debate. Prospective, randomized studies
are required to confirm the autoimmune diseases role in MDS prognosis.
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